The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) following second-line lenalidomide plus dexamethasone (LEN + DEX).
David Samuel DiCapua Siegel
Consultant or Advisory Role - Celgene; Merck; Millennium; Onyx
Honoraria - Celgene; Merck; Millennium; Onyx
Richy Agajanian
No relevant relationships to disclose
Rakesh Gaur
No relevant relationships to disclose
Kasra Karamlou
Consultant or Advisory Role - Genentech
Honoraria - Bristol-Myers Squibb; Celgene; Genentech; Incyte; Millennium; Pharmacyclics; Teva
Hakan Kaya
Consultant or Advisory Role - Celgene; Millennium; Onyx
Honoraria - Celgene; Millennium; Onyx
Michael Sturniolo
Employment or Leadership Position - Celgene
Rosanna J. Ricafort
Employment or Leadership Position - Celgene
Gail Larkins
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Shankar Srinivasan
Employment or Leadership Position - Celgene
Rajesh Chopra
Employment or Leadership Position - Celgene
Anjan Thakurta
Employment or Leadership Position - Celgene
Yasir M. Nagarwala
Employment or Leadership Position - Celgene
Flavio Kruter
No relevant relationships to disclose